By: Brian Feldt, St. Louis Business Journal
September 8, 2014
Tryton Medical, a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors that includes St. Louis-based RiverVest Venture Partners and the 3×5 Special Opportunity Fund.
Both RiverVest and the 3X5 fund, which is co-managed by RiverVest, have participated in funding rounds for Tryton before, most recently in a $24 million equity financing round for the Durham, North Carolina-based company in early 2013. Read more
ST. LOUIS and SAN DIEGO (Aug. 13, 2014) – Otonomy, Inc., a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering. (more…)
By Josh Baxt, BioSpace.com Exclusive Story
July 21, 2014
In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners run a biomedical adoption agency. They track down innovative discoveries, help raise them for a while and then find a good home, either at a pharmaceutical company or through public markets.
For cash-strapped startups, this represents an opportunity, but they need to understand the rules. RiverVest is trying to build companies in five years or less, and that means having excellent IP and a collaborative team to take it towards the finish line. Read More
Medical Device and Diagnostic Industry
May 28, 2014
No. 7: RiverVest Venture Partners
Passion or the desire to make a difference alone cannot bring about radical changes in the world of medtech. Money and the right guidance are equally crucial. That’s where venture capitalist firms—especially RiverVest Venture Partners—come in. Read More
RiverVest Venture Partners’ portfolio company Lumena is Sold to Shire for $260 million; Represents Sixth Exit from RiverVest Venture Fund II
ST. LOUIS and SAN DIEGO (May 12, 2014) – RiverVest Venture Partners today announced portfolio company Lumena Pharmaceuticals has been sold to Dublin-based Shire Plc., in a transaction with an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials. (more…)
RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner
ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner. (more…)
“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014. Read more
St. Louis Business Journal
March 7, 2014
Brian Feldt, Reporter
Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round.
RiverVest Venture Partners’ Bradley T. Keller Presents New Treatment for Cholestatic Liver Diseases at The Liver Meeting
ST. LOUIS and WASHINGTON, D.C. (Nov. 5, 2013) –RiverVest Venture Partners’ Bradley T. Keller presents research today on a potential new treatment for cholestatic liver diseases at The Liver Meeting in Washington, D.C. (more…)
July 15, 2013
ST. LOUIS (St. Louis Business Journal) — Abbott Laboratories is acquiring IDEV Technologies, a RiverVest Venture Partners medical device portfolio company, for $310 million… Read more.